AI-generated summary
This review describes androgenetic alopecia, the most common hair loss disorder in men and women, and how dihydrotestosterone drives follicle miniaturization and hair cycle changes. The authors note that minoxidil, finasteride, and photolaser therapy are the only FDA-approved medical treatments for the condition. The abstract provides no data on treatment outcomes or efficacy comparisons.
- Who or what was studied
- People with androgenetic alopecia, men and women
- Limits stated in the abstract
- The abstract is a general overview and does not report study-level data, outcomes, or the wavelengths used in photolaser therapy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Androgenetic alopecia. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.